- 3 - 
have in the past. As rDNA research and development spreads to 
a wider ranging field, it may be necessary to develop more than 
one set of guidelines. Du Pont believes, however, that at 
this time NIH should not restrict application of its Guidelines. 
Certainly, individual companies should not be discouraged from 
following those guidelines because the work being done is not 
"biomedical" . 
We trust that the above comments will be of assistance 
to you in your deliberation on this subject. 
Gerald A. Hapka 
Senior Attorney 
Environment, Materials and 
Logistics Division 
( 302 ) 774-9466 
GAH/cs 
[657] 
